Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects

Advanced Drug Delivery Reviews

Volumn 60, Issue 8, 2008, Pages 939-954

  Wong, Joseph ^a   Brugger, Andrew ^a   Khare, Atul ^a   Chaubal, Mahesh ^a   Papadopoulos, Pavlos ^a   Rabinow, Barrett ^a   Kipp, James ^a   Ning, John ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Extended release; Insoluble drug delivery; Intravenous injection; Nanoparticles; Poorly water soluble drugs; Safety

Indexed keywords

DRUG DELIVERY; DRUG DOSAGE; NANOPARTICLES; ONCOLOGY;

EXTENDED RELEASE; INSOLUBLE DRUG DELIVERY; INTRAVENOUS INJECTION; POORLY WATER SOLUBLE DRUGS;

SUSPENSIONS (FLUIDS);

ADIPIODONE; AMPHOTERICIN B LIPID COMPLEX; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CATIONIC SURFACTANT; DANTROLENE; DEOXYCHOLATE SODIUM; DILAUROYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; ENDOTOXIN; FLURBIPROFEN; GEMCITABINE; ITRACONAZOLE; LEUPRORELIN; LIPOSOME; MACROGOL; NANOCRYSTAL; NANOPARTICLE; PACLITAXEL; PERFLEXANE; PERFLUTREN; PHOSPHOLIPID; PIROXICAM; POLOXAMER; POLYGLACTIN; POLYSORBATE 80; POLYSTYRENE; SPARTAJECT; UNINDEXED DRUG; VINCRISTINE;

ALOPECIA; BACKACHE; BREAST CANCER; CANCER THERAPY; CARCINOGENIC ACTIVITY; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CRYSTALLIZATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG SOLUBILITY; DRUG WITHDRAWAL; EMULSION; HUMAN; INTRAVENOUS DRUG ABUSE; MUSCLE SPASM; NEOPLASM; NEUTROPENIA; NONHUMAN; PARTICLE SIZE; PERCUTANEOUS VERTEBROPLASTY; PHLEBITIS; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SCALE UP; SENSORY NEUROPATHY; SINGLE DRUG DOSE; SUSPENSION; TREATMENT INDICATION;

ANIMALS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; INJECTIONS, INTRAVENOUS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SUSPENSIONS;

EID: 42649115104     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.11.008     Document Type: Review

References (130)

1. Kipp J. The role of solid nanoparticle technology in the parenteral delivery of poor water-soluble drugs. Int. J. Pharm. 284 (2004) 109-122
2. Lipinski C. Drug-like properties and the cause of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000) 235-249
3. Lipinski C. Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 5 (2002) 82-85
4. Gupta K. Solutions and phase equilibria. In: Gennaro A. (Ed). Remington: The Science and Practice of Pharmacy. 20th Ed. (2000), Lippincott Williams & Wilkins, Baltimore 208-209
5. Yakowsky S. Solubility and Solubilization in Aqueous Media (1999), Oxford University Press, New York 67, 321-396, 426, 431
6. Rabinow B. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
7. Francois M., Snoeckx E., Putteman P., Wouters F., De Proost E., Delaet U., Peeters J., and Brewster M. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci 5 (2003) Article 5
8. Zuidema J., Pieters F., and Duchateau G. Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int. J. Pharm. 47 (1988) 1-12
9. Pace S., Pace G., Parikh I., and Mishra A. Novel injectable formulations of insoluble drugs. Pharm. Technol. 23 (1999) 116-134
10. Borm P., Klaessig F., Landry T., Moudgil B., Pauluhn J., Thomas K., Trottier R., and Wood S. Research strategies for safety evaluation of nanomaterials, Part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicol. Sci. 90 (2006) 23-32
11. Bummer P. Interfacial phenomena. In: Gennaro A. (Ed). Remington: The Science and Practice of Pharmacy. 20th Ed. (2000), Lippincott Williams & Wilkins, Baltimore 285
12. Gould L., Lansley A., Brown M., Forbes B., and Martin G. Mitigation of surfactant erythrocyte toxicity by egg phosphatidylcholine. J. Pharm. Pharmacol. 52 (2000) 1203-1209
13. Apte S., and Ugwu S. A review and classification of emerging excipients in parenteral medications. Pharm. Technol. 27 (2003) 46-60
14. Adler J., Singh P., Patist A., Rabinovixh Y., Shah D., and Moudgil B. Correlation of particulate dispersion stability with the strength of self-assembled surfactant films. Langmuir, 16 (2000) 7255-7262
15. Carthew D., Buckton G., Parsons G., and Poole S. The effect of temperature on the surface nature of an adsorbed layer of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) block copolymers. Pharm. Res. 13 (1996) 1730-1733
16. Chasteigner S., Cave G., Fessi H., Devissaguet J., and Puisieux F. Freeze-drying of itraconazole loaded nanosphere suspensions: a feasibility study. Drug Dev. Res. 38 (1996) 116-124
17. Owens D., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 1 (2006 Jan 3) 93-102
18. Moghimi S., Hunter A., and Murray J. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-318
19. Welin-Berger K., and Bergenstahl B. Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase. Int. J. Pharm. 200 (2000) 249-260
20. Mullin J. Crystallization. 4th Ed. (2004), Elsevier, Oxford 320-322
21. Swarbrick J., Rubino J., and Rubino O. Coarse dispersion. In: Gennaro A. (Ed). Remington: The Science and Practice of Pharmacy. 20th Ed. (2000), Lippincott Williams & Wilkins, Baltimore 322
22. Merisko-Liversidge E., Liversidge G., and Cooper E. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
23. Scholer N., Olbrich C., Tabatt K., Muller R., Hahn H., and Liesefeld O. Surfactant, but not the size of solid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int. J. Pharm. 221 (2001) 57-67
24. Muller R., Ruhl D., Runge S., Schulze-Forster K., and Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14 (1997) 458-462
25. Riess J., and Le Blanc M. Perfluorocompounds as blood substitutes. Angew. Chem. 17 (1978) 621-634
26. Dumortier G., Grossiord J., Agnely F., and Chaumeil J. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 23 (2006) 2709-2728
27. Mouton J., van Peer A., de Beule K., van Vliet A., Donnelly J., and Soons P. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple does of a novel formulation. Antimicrob. Agents Chemother. 50 (2006) 4096-4102
28. Schroeder H., Simmons G., and DeLuca P. Distribution of radiolabeled subvisible microspheres after intravenous administration to beagle dogs. J. Pharm. Sci. 67 (1978) 504-507
29. Chapter 788, Particle matter in injections, The United State Pharmacopeia, The National Formulary, USP30/NF25, vol. 1, The United State Pharmacopeial Convention, Rockville, 2007, pp. 321-327.
30. Lehr H., Brunner J., Rangoonwala R., and Kirkpatrick C. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in post ischemic striated muscle. Am. J. Respir. Crit. Care Med. 165 (2002) 514-520
31. Oh W., and Mital M. Fat embolism: current concepts of pathogenesis, diagnosis, and treatment, Orthop. Clin. North Am. 9 (1978) 769-779
32. Orenstein J., Sato N., Arcon B., Buchholz B., and Bloom S. Microemboli observed in deaths following cardiopulmonary bypass surgery: silicone antifoam agents and polyvinyl chloride tubing as sources of emboli. Human Pathol. 13 (1982) 1082-1090
33. Burton A., Rhines L., and Mendel E. Vertebroplasty and kyphoplasty: a comprehensive review. Neurosurg. Focus 18 (2005) 1-9
34. Douglas F., Fafilmout K., and Patt N. Foreign particle embolism in drug addicts: respiratory pathophysiology. Ann. Intern. Med. 75 (1971) 865-872
35. Ward S., Heyneman L., Reittner P., Kazerooni E., Godwin J., and Müller N. Talcosis associated with IV abuse of oral medications: CT findings. Am. J. Roentgenol. 174 (2000) 789-793
36. Pare J., Cote G., and Fraser R. Long-term follow-up of drug abusers with intravenous talcosis. Am. Rev. Respir. Dis. 139 (1989) 233-241
37. Overland E., Nolan A., and Hopewell P. Alteration of pulmonary function in intravenous drug abusers. Am. J. Med. 68 (1980) 231-237
38. Sieniewicz D., and Nidecker A. Conglomerate pulmonary disease: a form of talcosis in intravenous methadone abusers. Am. J. Roentgenol. 135 (1980) 697-702
39. Falchuk K., Peterson L., and McNeil B. Microparticle-induced phlebitis, its prevention by in-line filtration. N. Engl. J. Med. 312 (1985) 78-82
40. Taniguchi T., Yamamoto K., and Kobayashi T. Precipitate formed by thiopentone and vecuronium cause pulmonary embolism. Can. J. Anaesth. 45 (1998) 347-351
41. Yalkowsky S., Krzyzaniak J., and Ward G. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 87 (1998) 787-796
42. Garavilla L., Peltier N., and Merisko-Liversidge E. Controlling the acute hemodynamic effects associated with IV administration of particulate drug dispersions in dogs. Drug Dev. Res. 37 (1996) 86-96
43. Barber T. Pharmaceutical Particle Matter Analysis and Control (1993), Interpharm Press, Buffalo Grove, Illinois 50-142, 266-349, 294-303, 470-486
44. Neuberger D., and Wong J. Suspension for intravenous injection: image analysis of scanning electron micrographs of particles to determine size and volume. PDA J. Pharm. Sci. Technol. 59 (2005) 187-199
45. Wong J., Papadopoulos P., Werling J., Rebbeck C., Doty M., Kipp J., Konkel J., and Neuberger D. Itraconazole suspension for intravenous injection: determination of the real component of complete refractive index input for static light scattering particle sizing instrument. PDA J. Pharm. Sci. Technol. 60 (2006) 302-313
46. Tinke A., Vanhoutte K., De Maesschalck R., Verheyen S., and De Winter H. A new approach in the prediction of dissolution behavior of suspended particles by means of their particle size distribution. J. Pharm. Biomed. Anal. 39 (2005) 900-907
47. Kelly R., and Lerke S. Particle size measurement techniques selection within method development in the pharmaceutical industry. Am. Pharm. Rev. 8 (2005) 72-81
48. Hickey A., and Concessio N. Descriptors of irregular particle morphology and powder properties. Adv. Drug Deliv. Rev. 26 (1997) 29-40
49. Etzler F., and Deanne R. Particle size analysis: a comparison of various methods II. Part. Part. Syst. Charact. 14 (1997) 278-282
50. Guide to Selecting Refractive Index, Particle Size Distribution Analyzer Technical Note, TN118, Horiba Instruments, Inc., Irvine, CA (2004)
51. Toongsuwan S., Chang H., Li L., Stephens D., and Plichta-Mahmoud H. Particle size determination of a three-component suspension using a laser-scattering particle size distribution analyzer. Drug Dev. Ind. Pharm. 26 (2000) 895-900
52. Driscoll D., Etzler F., Barber T., Nehne J., Niemann W., and Bistrian B. Physicochemical assessments of parenteral lipid emulsions: light obscuration versus laser diffraction. Int. J. Pharm. 219 (2001) 21-37
53. Mattison K., Morfesis A., and Kaszuba M. A Primer on Particle Sizing using Dynamic Light Scattering, American Biotechnology Laboratory (December, 2003) 20-23
54. Bloomfield V. Static and dynamic light scattering from aggregating particles. Biopolymers 54 (2000) 168-172
55. Mu{double acute}ller H. Automated determination of particle-size distributions of dispersions by analytical ultracentrifugation. Colloid Polym. Sci. 267 (1989) 1113-1116
56. Barber D., Keuter J., and Kravig K. A logical stepwise approach to laser diffraction particle size distribution analysis development and validation. Pharm. Dev. Technol. 3 (1998) 153-161
57. Koster V., Kuks P., Lange R., and Talsma H. Particle size in parenteral fat emulsions, what are the true limitations?. Int. J. Pharm. 134 (1996) 235-238
58. Driscoll D. Lipid injectable emulsions: pharmacopeial and safety issues. Pharm. Res. 23 (2006) 1959-1969
59. Driscoll D. Stability and compatibility assessment techniques for total parenteral nutrition admixtures: setting the bar according to pharmacopeial standard. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 297-303
60. In-Process Revision, <729> Globule Size Distribution in Lipid Injectable Emulsions, Pharmaceutical Forum, Vol. 31 (5), The United States Pharmacopeial Convention, Rockville, September-October, 2005, 1448-1453.
61. Driscoll D., Nehne J., Peters H., Klu{double acute}tsch K., Bistrian B., and Niemann W. Physical assessments of lipid injectable emulsions via microscopy: a comparison methods proposed in United States pharmacopoeia chapter <729>. Int. J. Pharm. Compd. 10 (2006) 309-315
62. Tian Y., and Li L. Light-scattering method in particle size analysis of parenteral emulsions. Drug Dev. Ind. Pharm. 24 (1998) 275-280
63. Driscoll D., Parikh M., Silvestri A., Klu{double acute}tsch K., Bistrian B., and Nehne J. Establishing a stability window for medium-chain and long-chain-triglyceride lipid-based total nutrient admixtures using USP standards. Am. J. Health-Sys. Pharm. 63 (2006) 2135-2143
64. Driscoll D. Lipid injectable emulsions. Nutr. Clin. Prac. 21 (2006) 381-386
65. Injectable Preparations, British Pharmacopoeia vol. II (1980), Her Majesty's Stationary Office, London 578-580
66. Burnham W., Hansrani P., Knott C., Cook C., and Davis S. Stability of a fat emulsion based intravenous feeding mixture. Int. J. Pharm. 13 (1983) 9-22
67. Schwarz C., Mehnert W., Lucks J., and Müller R. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control. Release 30 (1994) 83-96
68. Gonyon T., Patel P., Owen H., Dunham A., and Carter P. Physiochemical stability of lipid injectable emulsions: correlating changes in large globule distributions with phase separation behavior. Int. J. Pharm. 343 (2007) 208-219
69. Chapter 905, Uniformity of Dosage Units, The United State Pharmacopeia, The National Formulary, USP30/NF25, Vol. 1, The United State Pharmacopeial Convention, Rockville, 2007, pp. 379-385.
70. Barash E., Newman A., Bates S., and Comella S. Amorphous pharmaceuticals. AAPS Newsmagazine (June, 2006) 30
71. Hancock B., and Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 (1997) 1-12
72. Kim S., Wei C., and Kiang S. Crystallization process development of an active pharmaceutical ingredient and particle engineering via the use of ultrasonics and temperature cycling. Org. Process Res. Dev. 7 (2003) 997-1001
73. Ende D., and Brenek S. Strategies to control particle size during crystallization process. Am. Pharm. Rev. 7 (2004) 98-104
74. Clement M., Pugh W., and Parikh I. Tissue distribution and plasma clearance of a novel microcrystal-encapsulated flurbiprofen formulation. Pharmacologist 34 (1992) 204
75. Oldshue J. Mixing of solid-liquid suspensions. J. Pharm. Sci. 50 (1961) 523-530
76. Oldshue J., Nerbst N., and Post T. A Guide to Fluid Mixing (1995), Lightnin, New York 1-27
77. Alvarez Nunez F., Yalkowsky S.,. Foaming activity and pKa of some surface active compounds. Int. J. Pharm. 151 (1997) 193-199
78. Block L. Process scale-up for pharmaceutical liquids and semisolids. Am. Pharm. Rev. 3 (2000) 30-33
79. Geankoplis C. Transport Processes and Unit Operations. 3rd Ed. (1978), Prentice-Hall, Englewood Cliffs 140-153
80. Nienow A. The suspension of solid particles. In: Harnby H., Edwards M., and Nienow A. (Eds). Mixing in the Process Industries. 2nd Ed. (2000), Butterwoth-Heinemann, Oxford 364-393
81. Chien Y., Przybyszewski P., and Shami E. Syringeability of nonaqueous parenteral formulations - development and evaluation of a testing apparatus. PDA J. Pharm. Sci. Technol. 35 (1981) 281-284
82. Chapter 1211, Sterilization and Sterility Assurance of Compendial Articles, The United State Pharmacopeia, The National Formulary, USP30/NF25, Vol. 1, The United State Pharmacopeial Convention, Rockville, 2007, pp. 669-674.
83. Dulmage H., Correa J., and Martinez J. Coprecipitation with lactose as a means of recovering the spore-crystal complex of Bacillus thuringiensis. J. Invertebr. Pathol. 15 (1970) 15-20
84. Abbott C., Cockton J., and Jones W. Resistance of crystalline substances to gas sterilization. J. Pharm. Pharmacol. 8 (1956) 709-720
85. Doyle J., and Ernst R. Resistance of Bacillus subtilis var. niger spores occluded in water-insoluble crystals to three sterilization agents. Appl. Microbiol. 15 (1967) 726-730
86. Mullican C., and Hoffman R. Dry heat or gaseous chemical resistance of Bacillus subtilis var. niger spores included within water-insoluble crystals. Appl. Microbiol. 16 (1968) 1110-1113
87. Wong J., Papadopoulos P., Rebbeck C., Schwabe S., Lischewski G., Melchert J., Kuu W., Agostinelli T., Smith T., Brame G., Lynn R., and Hepler D. Effect of terminal sterilization by irradiation on amber type I and type III glass containers containing veterinary oxytetracycline suspension. PDA J. Pharm. Sci. Technol., 58 (2004) 6-14
88. Reid B. Gamma processing technology: an alternative technology for terminal sterilization of parenterals. PDA J. Pharm. Sci. Technol. 49 (1995) 83-89
89. Zheng J., and Bosch H. Sterile filtration of NanoCrystal™ drug formulations. Drug Dev. Ind. Pharm. 23 (1997) 1087-1093
90. Moller N., and Jensen V. Studies on particle size problems-V. Surface area stabilities of micronized powders in relation to humidity and heat sterilization. Dansk Tidsskr. Farm. 44 (1970) 301-310
91. Friedman R., and Mahoney S. Risk factors in aseptic processing. Am. Pharm. Rev. 6 (2003) 44-47
92. Chapter 71, Sterility Tests, The United State Pharmacopeia, The National Formulary, USP30/NF25, Vol. 1, The United State Pharmacopeial Convention, Rockville, 2007, pp. 97-102.
93. Toguchi H. Sterility assurance of microspheres. J. Control. Release 62 (1999) 51-55
94. Chapter 85, Bacterial Endotoxins Test, The United State Pharmacopeia, The National Formulary, USP30/NF25, Vol. 1, The United State Pharmacopeial Convention, Rockville, 2007, pp. 109-113.
95. Chapter 151, Pyrogen Test, The United State Pharmacopeia, The National Formulary, USP30/NF25, Vol. 1, 2007, pp. 135-136.
96. Margolis J., McDonald J., Heuser R., Klinke P., Waksman R., Virmani R., Desai N., and Hilton D. Systemic nanoparticle paclitaxel (NAB-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. Clin. Cardiol. 30 (2007) 165-170
97. Olszanski A., Lewis L., Mita C., Walovitch R., Perez R., Tuck D., and Rowinsky E. Phase 1 and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system (HDDS) for paclitaxel, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. 22 (2004, July 15 Supplement) 2048
98. Straub J., Chickering D., Lovely J., Zhang H., Shah B., Waud W., and Bernstein H. Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm. Res. 22 (2005) 347-355
99. Kanke M., Simmons G., Weiss D., Bivins B., and DeLuca P. Clearance of 41Ce labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration in beagle dogs. J. Pharm. Sci. 69 (1980) 755-762
100. Singer J., Adlersberg L., Hoenig E., Ende E., and Tchorsch Y. Radiolabeled latex particles in the investigation of phagocytosis in vivo: clearance curves and histological observations. J. Reticuloendothel. Soc. 6 (1969) 561-589
101. Gesler R., Garvin P., Klamer B., Robinson R., Thompson C., et al. The biological effects of polystyrene latex particles administered intravenously to rats-a collaborative study. Bull. Parenter. Drug Assoc. 27 (1973) 101-113
102. Schroeder H., Simmons G., and Deluca P. Distribution of radiolabeled subvisible microspheres after intravenous administration to beagle dogs. J. Pharm. Sci. 67 (1978) 504-507
103. OPTISON™ (Perflutren Protein-Type A Microspheres for Injection, USP) Product Description, Amersham Health Inc. (June 2003)
104. DraxImage MAA Kit for the preparation of Technetium Tc99m Albumin Aggregated Injection. Product insert (February 2002)
105. Kreuter J. Nanoparticles. In: Kreuter J. (Ed). Colloidal Drug Delivery Systems (1994), Marcel Dekker, New York 219-315
106. Daemen T., Hofstede G., ten Kate M., Bakker-Woudenbert I., and Scherphof G. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer 61 (1995) 716-721
107. van Etten E., ten Kate M., Snijders S., and Bakker-Woudenberg I. Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system. Antimicrob. Agents Chemother. 42 (1998) 1677-1681
108. Bakker-Woudenberg I., ten Kate M., Storm G., and van Etten E. Administration of liposomal agents and the phagocytic function of the mononuclear phagocytic system. Int. J. Pharm. 162 (1998) 5-10
109. Pesko L. Physiological consequences of injected particulates. In: Knapp J.Z., Barber T.A., and Lieberman A. (Eds). Liquid- and Surface-Borne Particle Measurement Handbook (1996), Marcel Dekker, New York 661-686
110. Bogner J., Kronawitter U., Rolinski B., Truebenbach K., and Goebel F. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 7 (1994) 463-468
111. Daemen T., Regts J., Meesters M., ten Kate M., Bakker-Woudenberg I., and Scherphof G. Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Control. Release 44 (1997) 1-9
112. University of Alberta Drug Bank, July 12th, 2007, http://redpoll.pharmacy.ualberta.ca/drugbank/extrIndex.htm.
113. Rabinow B., and Chaubal M. Injectable nanoparticles for efficient drug delivery. In: Gupta R., and Kompella J. (Eds). Nanoparticle Technology for Drug Delivery (2006), Marcel Dekker, New York
114. Rupper A., and Cardelli J. Regulation of phagocytosis and endophagosomal trafficking pathways in Dictyostelium discoideum. Biochim.Biophys. Acta 1525 (2001) 205-216
115. Rabinow B., Kipp J., Papadopoulos P., Wong J., Glosson J., Gass J., Sun C., Wielgos T., White R., Cook C., Barker K., and Wood K. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 339 (2007) 251-260
116. Nyman D., Campbell K., Hersh E., Long K., Richardson K., Trieu V., Desai N., Hawkins M., and von Hoff D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 1 (2005) 7785-7793
117. Ibrahim N., Desai N., Legha S., Soon-Shiong P., Theriault R., Rivera E., Esmaeli B., Ring S., Bedikian A., Hortobagyi G., and Ellerhorst J. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8 (2002) 1038-1044
118. Ibrahim N., Samuels B., Page R., Doval D., Patel K., Rao S., Nair M., Bhar P., Desai N., and Hortobagyi G. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 23 (2005) 6019-6026
119. Stinchcombe T., Socinski M., Walko C., O'neil B., Collichio F., Ivanova A., Mu H., Hawkins M., Goldberg R., Lindley C., and Claire Dees E. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors. Cancer Chemother. Pharmacol. 60 (2007) 759-766
120. Moreno-Aspitia A., and Perez E. North Central Cancer Treatment Group N0531: phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer. Clin. Breast Cancer 6 (2005) 361-364
121. Olavarria E., Hassan M., Eades A., Nilsson C., Timms A., Matthews J., Craddock C., Kanfer E., Apperley J., and Goldman J. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 14 (2000) 1954-1959
122. Introgen Company Press Release, dated April 17, 2007. Introgen's Intravenous Nanoparticle Gene Therapy Shows Activity in Stage IV Lung Cancer Patients (cited on Introgen company website, http://www.introgen.com).
123. Walsh T., Hiemenz J., Seibel N., Perfect J., Horwith G., Lee L., Silber J., DiNubile M., Reboli A., Bow E., Lister J., and Anaissie E. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26 (1998) 1383-1396
124. Green M., Manikhas G., Orlov S., Afanasyev B., Makhson A., Bhar P., and Hawkins M. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 17 (2006) 1263-1268
125. van Arnum P. Nanotechnology advances in drug delivery. Pharm. Technol. 31 (2007) 48, 50, 52
126. Wilkins D., and Meyers P. Studies on the relationship between the electrophoretic properties of colloids and their blood clearance and organ distribution in the rat. Br. J. Exp. Pathol. 47 (1966) 568-576
127. Schoenberg M., Gilman P., Mumaw V., and Moore R. The phagocytosis of uniform polystyrene latex particles by the reticulo-endothelial system in the rabbit. Br. J. Exp. Pathol. 42 (1961) 486-495
128. Slack J., Kanke M., Simmons G., and DeLuca P. Acute hemodynamic effects and blood pool kinetics of polystyrene microspheres following intravenous administration. J. Pharm. Sci. 70 (1981) 660-664
129. J. Gass, Pathobiology, Baxter Healthcare Corporation, personal communication.
130. J. Gass, Pathobiology, Baxter Healthcare Corporation, personal communication.